Alzamend Neuro is trading 6.6% down at $1.13 as recent gains driven by softer inflation data and improving macro sentiment fade.
- Investors are rotating out of smaller biotech names despite modest strength in broader market indices.
- Today's decline follows a broader pattern of sector pressure and prior sharp declines highlighted in recent coverage.